Company family
Pro Doc: medicine shortages
As of 2 Nov 2026, 15 Pro Doc products have a reported shortage across 1 countries, covering 6 medicines.
Products short15rank #133 of 464
Medicines6active ingredients
Countries1/16
New in 90 days3-7 vs market pace
Typical duration4 monthsmedian so far
Manufacturing90%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Diltiazem | 4 | 3 Aug 2026 | Manufacturing problem | 7/16 | |
| Clonazepam | 3 | 4 Jul 2025 | Manufacturing problem | 4/16 | |
| Sitagliptin | 3 | not given | Not stated | 8/16 | |
| Gabapentin | 2 | 19 Jun 2026 | Manufacturing problem | 9/16 | |
| Metformin and Sitagliptin | 2 | not given | Not stated | 3/16 | |
| Trandolapril | 1 | 30 Jun 2026 | Distribution or logistics | 4/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.